AML in first or second remission
Item
diagnosis of acute myeloid leukemia, in first or second remission.
boolean
C0023467 (UMLS CUI [1,1])
C0544452 (UMLS CUI [1,2])
C0205435 (UMLS CUI [1,3])
C0023467 (UMLS CUI [2,1])
C0544452 (UMLS CUI [2,2])
C0205436 (UMLS CUI [2,3])
age
Item
age 55 or older
boolean
C0001779 (UMLS CUI [1])
informed consent
Item
patients must have given signed, informed consent prior to registration on study.
boolean
C0021430 (UMLS CUI [1])
complete remission
Item
participants must have attained a complete remission (cr) to induction chemotherapy and are not good candidates for further intensive chemotherapy or a transplant.
boolean
C0677874 (UMLS CUI [1])
childbearing potential negative pregnancy test
Item
female patients of childbearing potential must have a negative serum pregnancy test within 2 weeks prior to enrollment.
boolean
C3831118 (UMLS CUI [1])
C0032976 (UMLS CUI [2])
contraception duration
Item
male and female patients must use an effective contraceptive method during the study and for a minimum of 6 months after study treatment.
boolean
C0449238 (UMLS CUI [1,1])
C0032976 (UMLS CUI [1,2])
APL
Item
patients with a diagnosis of acute promyelocytic leukemia are not eligible.
boolean
C0023487 (UMLS CUI [1])
concurrent therapy
Item
participants cannot be currently receiving chemotherapy, radiation therapy, or immunotherapy.
boolean
C0392920 (UMLS CUI [1,1])
C0205420 (UMLS CUI [1,2])
C1522449 (UMLS CUI [2,1])
C0205420 (UMLS CUI [2,2])
C0021083 (UMLS CUI [3,1])
C0205420 (UMLS CUI [3,2])
investigational agents
Item
patients must not be receiving any other investigational agents.
boolean
C1875319 (UMLS CUI [1])
hiv, hepatitis b or c
Item
participants cannot have hepatitis b or c or hiv.
boolean
C0019682 (UMLS CUI [1,1])
C0019163 (UMLS CUI [1,2])
C0019196 (UMLS CUI [1,3])
infection
Item
patients must not have an uncontrolled infection
boolean
C0009450 (UMLS CUI [1])